Proteomics and ovarian cancer: Integrating proteomics information into clinical care : Current status of cancer proteomics, how far are we from clinical applicationHAYS, John L; KIM, Geoffrey; GIUROIU, Julia et al.Journal of proteomics (Print). 2010, Vol 73, Num 10, pp 1864-1872, issn 1874-3919, 9 p.Article

Proteomic biomarkers for overall and progression-free survival in ovarian cancer patientsHØGDALL, Estrid; FUNG, Eric T; HØGDALL, Claus et al.Proteomics. Clinical applications (Print). 2010, Vol 4, Num 12, pp 940-952, issn 1862-8346, 13 p.Article

Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancerENA WANG; NGALAME, Yvonne; MARINCOLA, Francesco M et al.Clinical cancer research. 2005, Vol 11, Num 1, pp 113-122, issn 1078-0432, 10 p.Article

Ovarian Cancer: Biomarker Proteomic Diagnosis in ProgressYONG ZHANG; BIN GUO; RAN BI et al.Applied biochemistry and biotechnology. 2012, Vol 168, Num 4, pp 910-916, issn 0273-2289, 7 p.Article

Ovarian cancerJAYSON, Gordon C; KOHN, Elise C; KITCHENER, Henry C et al.Lancet (British edition). 2014, Vol 384, Num 9951, pp 1376-1388, issn 0140-6736, 13 p.Article

Dépister le cancer de l'ovaireAGOPIAN, Anahid; ALEXANDRE, Jérôme.La Revue du praticien. Médecine générale. 2014, Num 925, pp 558-559, issn 0989-2737, 2 p.Article

TR3 Modulates Platinum Resistance in Ovarian CancerWILSON, Andrew J; LIU, Annie Y; FADARE, Oluwole et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 15, pp 4758-4769, issn 0008-5472, 12 p.Article

En cas de chirurgie sub-optimale: Existe-t-il un nouveau traitement standard dans le cancer de l'ovaire ?DONNADIEU, Anne; DE LA MOTTE ROUGE, Thibault.Onko +. 2013, Vol 5, Num 40, pp 7-9, issn 2101-9495, 3 p., CAH2Article

Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomicsSHIELD-ARTIN, Kristy L; BAILEY, Mark J; OLIVA, Karen et al.Proteomics. Clinical applications (Print). 2012, Vol 6, Num 3-4, pp 170-181, issn 1862-8346, 12 p.Article

Wild-Type Tumor Repressor Protein 53 (TRP53) Promotes Ovarian Cancer Cell SurvivalMULLANY, Lisa K; ZHILIN LIU; KING, Erin R et al.Endocrinology (Philadelphia). 2012, Vol 153, Num 4, pp 1638-1648, issn 0013-7227, 11 p.Article

The invisible worm: ovarian cancerREEVE, Gill; MACKAY-THOMAS, Stuart.BMJ. British medical journal (International ed.). 2009, Vol 338, Num 7709, pp 1498-1500, issn 0959-8146, 3 p.Article

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical OutcomeTOTHILL, Richard W; TINKER, Anna V; TRAFICANTE, Nadia et al.Clinical cancer research (Print). 2008, Vol 14, Num 16, pp 5198-5208, issn 1078-0432, 11 p.Article

Gonadotropins and ovarian cancerCHOI, Jung-Hye; WONG, Alice S. T; HUANG, He-Feng et al.Endocrine reviews. 2007, Vol 28, Num 4, pp 440-461, issn 0163-769X, 22 p.Article

Immunologic approaches to ovarian cancer treatmentSABBATINI, Paul; ODUNSI, Kunle.Journal of clinical oncology. 2007, Vol 25, Num 20, pp 2884-2893, issn 0732-183X, 10 p.Article

Systemic therapy for ovarian cancer : Current status and New TreatmentsOZOLS, Robert F.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S3-S11, SUP6Article

An interdisciplinary approach to ovarian cancerVERMORKEN, Jan B; SAIP, Pinar; DU BOIS, Andreas et al.Annals of oncology. 2006, Vol 17, issn 0923-7534, x233-x250, SUP10Conference Paper

Apolipoprotein E is required for cell proliferation and survival in ovarian cancerCHEN, Yu-Chi; POHL, Gudrun; WANG, Tian-Li et al.Cancer research (Baltimore). 2005, Vol 65, Num 1, pp 331-337, issn 0008-5472, 7 p.Article

Ascitic complement system in ovarian cancerBJØRGE, L; HAKULINEN, J; VINTERMYR, O. K et al.British journal of cancer. 2005, Vol 92, Num 5, pp 895-905, issn 0007-0920, 11 p.Article

Targeted gene therapy for ovarian cancerROCCONI, Rodney P; NUMNUM, T. Michael; STOFF-KHALILI, Mariam et al.Current gene therapy. 2005, Vol 5, Num 6, pp 643-653, issn 1566-5232, 11 p.Article

3rd International Ovarian Cancer Consensus Conference : outstanding issues for future considerationSTUART, G; AVALL-LUNDQVIST, E; FUJIWARA, K et al.Annals of oncology. 2005, Vol 16, pp viii36-viii38, issn 0923-7534, SUP8Conference Paper

Oncogenic role of eIF-5A2 in the development of ovarian cancerGUAN, Xin-Yuan; FUNG, Jackie M-W; SHAM, Jonathan S. T et al.Cancer research (Baltimore). 2004, Vol 64, Num 12, pp 4197-4200, issn 0008-5472, 4 p.Article

Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cellsSHETTY, Vivekananda; NICKENS, Zacharie; TESTA, James et al.Journal of proteomics (Print). 2012, Vol 75, Num 11, pp 3270-3290, issn 1874-3919, 21 p.Article

Cancer de l'ovaire : Les cancers gynéco-mammairesGHAZLI, M; ENNACHIT, M; OUADIRGA, F et al.Espérance médicale. 2011, Vol 18, Num 177, pp 220-224, 5 p.Article

Common variants at 19p13 are associated with susceptibility to ovarian cancerBOLTON, Kelly L; TYRER, Jonathan; WEIDHAAS, Joanne et al.Nature genetics. 2010, Vol 42, Num 10, pp 880-884, issn 1061-4036, 5 p.Article

Inherited Determinants of Ovarian Cancer SurvivalGOODE, Ellen L; MAURER, Matthew J; CLIBY, William A et al.Clinical cancer research (Print). 2010, Vol 16, Num 3, pp 995-1007, issn 1078-0432, 13 p.Article